Atlas FDA

FoundationOne Liquid CDx (F1 Liquid CDx)

FDA premarket approval P200006/S003 · decided 2022-10-28

Approval details

PMA number
P200006
Supplement
S003
Supplement type
Normal 180 Day Track No User Fee
Supplement reason
Postapproval Study Protocol
Trade name
FoundationOne Liquid CDx (F1 Liquid CDx)
Generic name
Next generation sequencing oncology panel, somatic or germline variant detection system
Applicant
Foundation Medicine, Inc.
Date received
2022-09-30
Decision date
2022-10-28
Days to decision
28 days
Decision code
APPR
Product code
PQP
Advisory committee
Pathology
Expedited review
No
Location
Cambridge, MA
Statement
Approval for the termination of the post-approval study (PAS) protocol.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.